Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S

Precision medicine has revolutionized the treatment of patients in EGFR driven non-small cell lung cancer (NSCLC). Targeted drugs show high response rates in genetically defined subsets of cancer patients and markedly increase their progression-free survival as compared to conventional chemotherapy....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Chemical science (Cambridge) 2019-12, Vol.1 (46), p.1789-181
Hauptverfasser:	Lategahn, Jonas, Keul, Marina, Klvekorn, Philip, Tumbrink, Hannah L, Niggenaber, Janina, Mller, Matthias P, Hodson, Luke, Flahoff, Maren, Hardick, Julia, Grabe, Tobias, Engel, Julian, Schultz-Fademrecht, Carsten, Baumann, Matthias, Ketzer, Julia, Mhlenberg, Thomas, Hiller, Wolf, Gnther, Georgia, Unger, Anke, Mller, Heiko, Heimsoeth, Alena, Golz, Christopher, Blank-Landeshammer, Bernhard, Kollipara, Laxmikanth, Zahedi, Ren P, Strohmann, Carsten, Hengstler, Jan G, van Otterlo, Willem A. L, Bauer, Sebastian, Rauh, Daniel
Format:	Artikel
Sprache:	eng
Schlagworte:	Binding Cancer therapies Chemistry Chemotherapy Coordination compounds Crystal structure Crystallography Drugs Growth factors Inhibitors Kinases Resistance factors Selectivity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!